The symptoms and treatments for nasal obstruction are numerous and common. Yet, a consensus on a surgical approach or, even more importantly, how to define the success of any approach is lacking in the literature. A disease-specific outcomes instrument recently developed by the American Academy of Otolaryngology, known as the Nasal Obstruction Symptom Evaluation (NOSE) scale, has allowed for a validated, uniform method to compare different treatments for nasal obstruction.
INTRODUCTION
The symptom of nasal obstruction is a very common clinical entity. It has been reported that up to 25% of the population suffers from nonallergic nasal obstruction. 1 Treatment of nasal obstruction is equally common. In 1992, septoplasty was reported to be the third most commonly performed procedure and turbinate surgery the eighth most common procedure performed by otolaryngologists. 2 Surgical correction of visible anatomic deformities in the nose does not always guarantee a successful outcome of symptom relief. 3 The etiology of nasal obstruction is diverse and not always intuitive. Although up to 42% of the population may have some form of a septal deviation and compensatory turbinate hypertrophy, only a quarter of these patients may report symptoms of nasal obstruction. 4 This point highlights one of the well-described deficiencies in treating nasal obstruction. For over 100 years, despite scientific advances in objective criteria and methods to reliably measure nasal function, little correlation between objective findings and patient subjective symptoms of nasal obstruction can be found consistently in the literature. 3, [5] [6] [7] [8] [9] [10] [11] The surgical treatment of nasal obstruction has come a long way since the original description by Blandin of the "punch" procedure used to forcibly reverse septal deformities almost 200 years ago. 12 Anatomy, allergy, and sinus disease are all known to contribute to nasal obstruction. Today, there is no universal standard to objectively measure, report, treat, or assess subjective outcomes of nasal obstruction. With a reported failure rate of approximately 15% to 50% associated with septoplasty, new treatment options continue to be explored. 10, [13] [14] [15] [16] [17] Even with septoplasty performed at a rate of 15 procedures per 10,000 insured patients, the literature as of 1994 provided only weak evidence of the effectiveness of the procedure, with most studies providing level three evidence. 18 One explanation for this is that there are few validated patient-based instruments that are specific to nasal obstruction. For nasal obstruction, the most widely used instrument has been the visual analogue scale (VAS). 19 Used as a single-item scale, the VAS has been shown to be sensitive to small changes in health status after therapy. 20 Because the VAS is a single-item scale, the type of scale used and the construct of the question associated with the scale can dramatically effect the precision of the cross-sectional measurement of a symptom. 21 This is particularly true when it is used to detect change in a low-intensity symptom such as nasal obstruction. For nasal obstruction, standardization of the type of scale used, how it is delivered, as well as validation of the construct of the questions used are not supported in the literature.
A powerful tool to detect effectiveness of treatment came with development of outcomes research techniques. Originating in 1970s, outcomes research grew out of the study of the geographic variation and appropriateness of medical care. 22 Outcomes research uses validated questionnaires called instruments to study the effects of diverse therapies on a patient's health-related quality of life (HRQL). 23 Outcomes research differs from traditional clinical research in that the former uses an observational design to measure response to treatment from the patient's perspective in a "real-world" setting rather than in a highly selected and constrained experimental setting. 24 Expanded measures of outcomes are studied through a nonrandomized design that includes patient-based measures of symptoms, functional status, emotional consequences of a disease and its treatment, and satisfaction with care. 25 Outcomes research provides level two evidence-based research. 26 The most widely used instrument for general health and the best example of a "generic" HRQL instrument is the Medical Outcomes Study Short-form 36-item Health Survey. 27 Generic instruments are valuable when comparing outcomes across different populations and interventions to detect large effects on HRQL. 28 Disease-specific instruments have been shown to be superior to generic health-status instruments when the burden of the disease studied is lower than the threshold detected by a generic HRQL questionnaire. 29 For the study of rhinology, several validated, disease-specific instruments have been developed. These include the Rhinosinusitis Quality of Life Survey, 30 the Chronic Sinusitis Survey, 31 the Rhinoconjunctivitis Quality of Life Questionnaire, 32 the Rhinosinusitis Disability Index, 33 the Sino-Nasal Outcome Tool, 34 and the Allergy Outcome Survey. 35 Although specific to sinus disease and allergy, none of these instruments are specific to nasal obstruction.
To fill this void, the American Academy of Otolaryngology commissioned a study to develop a disease-specific outcomes instrument for nasal obstruction, known as the Nasal Obstruction Symptom Evaluation (NOSE) scale (Fig. 1) . 7 This validated instrument has been used to study the effectiveness of septoplasty with or without turbinate surgery for the treatment of nasal obstruction. 8 The study did confirm a very large clinical and statistical beneficial effect of septoplasty with or without turbinate obstruction in patients with nasal obstruction. The study also demonstrated an unexpected trend found in multiple outcomes-based studies: a poor correlation between patient-based quality of life outcomes and physical or anatomic findings as reported by the physician. In other words, the physical findings and objective tests that are used to define nasal obstruction clinically do not always predict the patient's posttreatment perception of the benefit from the treatment. This has significant relevance to the physician when choosing strategies to affect nasal obstruction.
Although the study demonstrated that a septoplasty with or without a turbinate reduction was an effective treatment for nasal obstruction, it did not address the effect of treating the turbinates alone. The associated pathologic changes of the inferior turbinate secondary to septal deviation are well described. 9, 36 Because of the recognized compensatory turbinate hypertrophy on the concave side of the deviation, treatment of turbinate hypertrophy in addition to the septal deviation has been shown to lead to an increased success in relief of patients' nasal obstruction symptoms. Anatomically, this has clinical correlation because the resistance of the nasal airway has been shown to significantly increase over the anterior portion of the inferior turbinate and the nasal valve region. 37, 38 The physics established with Poiseuille's Law demonstrate that as little as a 10% reduction in the crosssectional area of the nasal passage can produce a 21% increase in the airflow through the nose. Decongestion of the nose has been shown to increase the total volume of the nasal cavity by 35%. 38 Studies using external nasal dilators have shown that 70% of the effects on nasal resistance caused by decongestants can be achieved with external nasal dilators. 39 These effects occur in the region of the nasal valve and the anterior region of the inferior turbinate, and these findings are most dramatic in patients with septal deviation. Given that the predominate effect of decongestants is vasoconstriction of the inferior turbinate, and given that the anterior portion of the inferior turbinate is intimately associated with the region of the nasal valve area, it is likely that reducing the size of the turbinates can produce a significant change in nasal obstruction, even in the presence of a septal deviation. It is not clear, however, how much subjective improvement can be achieved through avoiding or correcting the septal deviation and instead primarily treating the turbinate hypertrophy.
Recent advances in turbinate surgery have allowed for in-office procedures to be performed with minimal morbidity and requiring no nasal packing compared with the in-hospital septoplasty procedure. Originally described by Powell et al. 40 in 1996 and approved by the U.S. Food and Drug Administration in 1998, radiofrequency tissue reduction (RFTR) has emerged as a new and possibly costeffective in-office treatment option for the nasal airway obstruction. Since then, 11 studies have been undertaken to evaluate the short-and long-term effects of bilateral radiofrequency inferior turbinate reduction (BRITR) ( Table I) . Through targeted and controlled dosing, RFTR creates a submucosal lesion that allows for the preservation of mucociliary function while achieving tissue volume reduction. The submucosal lesion is a result of low-frequency frictional forces between ions in tissue at the cellular level. The ions rapidly change direction because of an alternating current produced by the electrode. This resulting ionic frictional force results in the generation of heat from the surrounding tissue, rather than emanating directly from the electrode itself. Unlike electrocautery or laser, which can produce tissue temperatures as high as 800°C, the radiofrequency technique uses a low power level to generate a temperature less than 85°C. This allows for a more controlled lesion without the risk for destruction of the overlying mucosa or necrosis of the turbinate bony architecture. Only one previous study has explored the use of BRITR in patients with mild to moderate septal deviation. 46 Despite no correction of the septal deviation in that study, significant improvement was noted on a VAS and acoustic rhinometry with BRITR only.
The findings of this study and the disproportionate ease of tolerance, cost, and performance of the procedure compared with septoplasty raise an interesting question.
Should patients with nasal obstruction and the findings of both septal deviation and turbinate hypertrophy be initially offered a less expensive in-office procedure with minimal postoperative morbidity and recovery or a more expensive outpatient surgical procedure that requires general anesthesia and an associated higher morbidity? How effective is BRITR compared with septoplasty in the treatment of this nasal obstruction? With the development of the NOSE survey, outcomes can now be more easily compared.
METHODS

Study Design and Patient Sample
Patients with the symptom of nasal obstruction and the clinical finding of both turbinate hypertrophy and septal deviation who met the inclusion criteria were enrolled in a prospective, nonrandomized study that used the NOSE survey. Inclusion criteria included a minimum of 3 months duration of nasal obstruction combined with the clinical findings of a clinically significantly deviated septum and turbinate hypertrophy as determined by the treating physician. All patients reported inadequate symptomatic relief after a minimum of 2 months medical therapy of nasal steroids, antihistamines, or oral decongestants from either their primary care physician or the treating surgeon. Exclusion criteria were an active nasal or sinus infection, nasal polyps, severe septal deformity producing near total obstruction, septal perforation, previous head and neck cancer, head and neck radiation, rhinoplasty, facial anomalies, autoimmune disease, vascular disorder, connective tissue disorder, bleeding disorder, uncontrolled asthma, pregnancy, or illiteracy.
Patient's subjective degree of nasal obstruction was recorded through self-reporting via the NOSE survey. The treating physician during the initial examination recorded anatomic findings of turbinate hypertrophy and any correlating septal deviation as a percentage of obstruction. Acoustic rhinometry and rhinomanometry were not performed because of a lack of consensus in the literature on their correlation with patient-based subjective reporting.
Institutional review board approval was sought and obtained prior to study initiation. Each patient entering the study signed consent for treatment and an amended Health Insurance 
Treatment
All BRTIR procedures were preformed in an office setting. All septoplasty procedures were performed in a hospital-based outpatient setting. Patients were treated with either BRITR only or BRITR with septoplasty according to the physician's recommendation and the patient's wishes. No assigned randomization or treatment allocation was made.
Patients receiving BRITR were treated using a Somnoplasty TCRF GII Generator system (Gyrus ENT, LLC, Bartlett, TN). Topical 4% Pontocaine was sprayed in each nasal cavity prior to injection of 3 to 4 mL of 1% lidocaine with 1:200,000 epinephrine or 1% lidocaine without epinephrine, depending on the cardiac history of the patient, into each turbinate. The electrode was placed at three to five locations within the inferior turbinate, and 300 to 600 J were delivered within each lesion at 75°C and 15 W. Progression of the lesions was from an anterior/superior to posterior/inferior location. A total of 1,400 to 1,800 J was delivered to each inferior turbinate. Hemostasis was achieved with NeoSynephrine-soaked pledgets that were removed after 5 minutes. The patient was observed for approximately 5 minutes for any residual bleeding prior to discharge from the clinic without nasal packing. Patients undergoing a septoplasty had a submucous resection of the deviated septal cartilage without a rhinoplasty or any manipulation of the alar cartilages with or without nasal packing.
Data Collection and Management
Patients who met eligibility criteria and consented to participating in the study were given a NOSE questionnaire (Fig. 1) to complete prior to treatment and at 3 and 6 months posttreatment. Data were collected either at a scheduled follow-up, by mail, or by telephone. No physician participated in, nor was physically present for, the data collection.
Analysis
Database management, data entry, and statistical analysis were performed through the Duke Clinical Research Institute, Duke University, Durham, North Carolina. Wilcoxon signed rank test was used for nonparametric analysis of the baseline and follow-up NOSE scores for intra-and intergroup analysis. Linear regression was performed to assess predictors of improvement through the establishment of forward entry of variables after identification of the normal distribution of the dependent variable. Univariate analysis was also performed via the nonparametric Spearman correlation coefficient. Statistical significance was defined as a P value of less than .05. For items not achieving statistical significance, statistical power was established using a t test at 5% significance level. Analysis of clinical change was performed using a distribution-based assessment, with a large, clinically important effect being defined as a change of greater than 0.8 times the SD of the mean pre-intervention score. 52 
RESULTS
Of the 106 patients who qualified for study participation and were initially enrolled, 77 (72.6%) completed the full 6 month NOSE evaluation follow-up and were included in the data analysis. Sixty-eight patients were in the group that received only BRITR, and nine patients were in the group that received both BRITR and a septoplasty. The mean age for both groups was 44.1 years; 53.2% were female, and 46.8% were male; 83.1% had no prior history of smoking; 67.5% had a history of undergoing previous allergy testing; 35 .1% were currently on immunotherapy for seasonal allergy; and 83.4% reported no history of headaches.
Baseline NOSE scores, and those at 3 and 6 months after surgical intervention, are seen in Table II . At 3 months, only the BRITR group was significantly improved (P Ͻ .001). At 6 months, the difference between baseline scores was significantly improved for both BRITR only and for BRITR/septoplasty (P Ͻ .001 and P ϭ .023, respectively). No statistical difference in the amount of improvement was noted between the two treatment groups at 3 or 6 months (Wilcoxon rank sum, P ϭ .304 with 63% power by t test at 5% significance level and P ϭ .747 with 5% power by t test at 5% significance level, respectively) (Tables III and IV) . Despite the lack of statistical significance, the possibility of a type II error does exist because of the relatively small sample size.
An almost equally large clinical effect was noted within each treatment group. For the BRITR group, the baseline SD was 26.06, and the mean change in scores was 31.92 at 3 months and 30.77 at 6 months. Thus, improvement was 1.22 and 1.18 times the SD, respectively. For the BRITR/septoplasty group, the baseline SD was 22.36, and the mean change at 3 months was 22.22 and 29.44 at 6 months. For this group, the improvement was measured to be 0.99 and 1.32 times the SD. This analysis shows that each group did in fact not only possess a statistically significant difference in change from their respective baseline scores but also demonstrated a large, clinically important effect.
Clinical and demographic variables were evaluated for predictive effects on the postoperative outcomes. Baseline variables of sex, age, history of allergy testing, history of smoking, current and prior treatment with immunotherapy, headache, and baseline overall NOSE score were evaluated. We found that only the baseline overall score was significantly predictive of change in the overall NOSE score at 6 months (Fig. 2) . Females trended toward a greater mean reduction in overall score (-38.18) compared with males (-23.29); however, this did not reach statistical significance (P ϭ .061). Overall score is sum of mean (SD) values on the variables (Congestion, Blockage, Breathing, Sleeping, Exertion) that has been converted to a scale of 0 to 100. The higher score represents worse nasal obstruction.
BRITR ϭ bilateral radiofrequency inferior turbinate reduction; Septo ϭ septoplasty.
No major or minor complications were reported in either group. The vast majority of patients (92.1%) receiving BRITR only reported no absence from work or school postoperatively compared with 44% of the group receiving BRITR/septoplasty. It should be noted that the majority of the BRITR/septoplasty patients had their procedure performed as an outpatient on a Friday and did not have nasal packing placed postoperatively.
At the 6-month follow-up, patients were asked several additional health-status questions. When asked about the amount of medicine taken since the procedure, the BRITR only patients reported taking significantly less medicine postoperatively than the BRITR/septoplasty patients (P ϭ .012) (Fig. 3) . No statistical difference was noted between the two groups in their reporting of how often they had felt sick or how many times they had to visit their physician since their procedure (P ϭ .314 and P ϭ .548, respectively) (Figs. 4 and 5).
DISCUSSION
The BRITR NOSE findings presented here are similar to those reported by Stewart et al. 8 for septoplasty (Fig. 6) . In that study, 59 subjects were treated with septoplasty with or without turbinate reduction in a prospective, nonrandomized, multi-institutional setting. Both groups of patients, septoplasty with turbinate reduction (n ϭ 43) and septoplasty alone (n ϭ 16), demonstrated very significant improvement from their respective baseline scores (P Ͻ .0001) at the end of 6 months. There was no significant difference between the two groups (P ϭ .27 at 3 mo and P ϭ .62 at 6 mo). Evaluation of clinically significant change yielded evidence of a large, clinically important effect for both groups, with a change in the SD of the mean preintervention score of twice the SD. The study reported no correlation between the physician-rated severity of the septal deviation or turbinate hypertrophy and the patient's self-reported NOSE scores at baseline or with improvement after treatment.
The Stewart et al. study did not have a treatment arm in which only a turbinate reduction was performed. Thus, it is not possible to compare the effect of treating the turbinate hypertrophy rather than the septal pathology. Given the lack of correlation between the surgeon's clinical evaluation and the patient's reported response to treatment, it is hard to conclude that a septoplasty, although proven as clinically effective, should be the primary method of treatment of nasal obstruction because we do not know the impact that was made on the patient's symptoms with the reduction of the turbinate hypertrophy alone without addressing the septal deviation.
The current study presented here represents the first use of the NOSE survey for BRITR or any other technique of turbinate surgery as a stand-alone procedure for nasal obstruction when septal deviation is present. This study also represents only the second study reporting the use of BRITR as a primary treatment in patients with nasal obstruction and the clinical findings of a septal deviation and turbinate hypertrophy. 46 Based on the distributionbased assessment of clinical change, BRITR was shown to have a large, clinically important effect in patients with the combined pathology of a septal deviation and turbinate hypertrophy and with the complaint of nasal obstruction. In comparing the NOSE scores with this current study and those of Stewart et al., a similar trend in the three treatment modes are seen (Fig. 6 ). 8 All groups in both studies reported significant changes in NOSE scores from baseline regardless of the method of treatment. Significance between septoplasty alone or septoplasty with turbinate reduction was not found in the Stewart et al. study, nor was it found between BRITR only or septoplasty with BRITR in this current study. It is important to note that both studies demonstrated a large clinical effect resulting from the treatment Power t test at 5% significance level -46%
BRITR ϭ bilateral radiofrequency inferior turbinate reduction.
within each group and that the effect was nearly equivalent across the three treatment groups compared in each study.
The combined results of these two studies are similar to those found in our retrospective pilot study, which compared all three treatment groups. Despite using a generic HRQL instrument, no statistical difference in the perceived patient self-reported benefit from the respective therapy received was seen.
In the present NOSE study, cost of delivery of care in the two treatment groups was monitored. The estimated total cost, defined as the average insurance payment for the procedure for the 68 patient, office-based BRITR group was approximately $34,000. Because fee schedules of hospitals are proprietary information, we cannot report the actual cost for delivery of care for the BRITR/septoplasty group. However, national cost trends for hospital charges relating to septoplasty are available. 53 In 2003, the national average hospital charge for a septoplasty performed in a hospital setting was $12,582. For the BRITR/septoplasty group, the national average for the hospital facility charge alone for the nine patients would be over $113,238. This excludes charges associated with anesthesia services and the surgeon's fee.
In this study, the BRITR only group would have no hospital facility fee charge or anesthesia charge associated with the delivery of their care. With these assumptions, it is probable that the cost of treating 68 patients with an in-office BRITR is likely close to the total cost of treating nine patients with a hospital-based septoplasty when actual allowable fee schedule payments for hospital facility fee, anesthesia services, and surgeon's fee are applied. In today's managed care environment, there is little doubt that an office-based procedure is far less expensive than a hospital-based procedure for services covered within a private or government sponsored health care plan.
A weakness of the current prospective is a lack of a control group. Although there is no placebo for septoplasty other than a sham procedure performed under risks of general anesthesia, BRITR can easily be presented as a blinded procedure for a control group and has been done so successfully in other studies. 47, 49 As a Fig. 2 . Regression analysis of the predictive effects on postoperative outcomes of baseline overall Nasal Obstruction Symptom Evaluation (NOSE) at 6 months following treatment. nonrandomized study, selection bias is a concern, especially when performed in a single institutional setting. The selection between BRITR and septoplasty can have significant bias when one procedure is performed in an office setting compared with another that is performed in a hospital setting. This likely was a contributor in the discrepancy of distribution seen in the treatment options within this study. The low number of patients in the BRITR/septoplasty group presents the possibility of a type II statistical error when comparing the effect between the two treatment groups. With 5% statistical power, more study is needed to compare these two treatment algorithms with larger numbers of patients.
CONCLUSION
Outcomes research tools such as the NOSE survey offer a new paradigm of clinical analysis that puts the patient rather than the surgeon in control of future definitions of clinical success. Compared with a VAS instrument, a validated, disease-specific, multi-item instrument allows a more dimensional assessment of the constructs and factors involved in the development of a patient's perception of their response to therapy through its discrimination and reproducibility. In today's medical economic environment, in which the patient is financially responsible for more of the total health care cost, it will become difficult to ignore the patient's perception of the impact of the care they have received. This perception will likely play a more central role in the development of treatment strategies than will the traditional physicianrated assessments that have defined many of today's current therapies. For nasal obstruction, this study supports a reevaluation of surgical paradigms after the failure of medical therapy in patients with the physical findings of both a septal deviation and turbinate hypertrophy. Fig. 6 . Comparison of the baseline, 3 months and 6 months posttreatment Nasal Obstruction Symptom Evaluation (NOSE) scores, with the current study and those of Stewart et al. 8 Higher NOSE score relates to greater symptoms of nasal obstruction.
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